NL-OMON46995招募中2 期
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy - Pembrolizumab (MK-3475) in high risk NMIBC patients unresponsive to BCG
Merck Sharp & Dohme (MSD)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Have a histologically-confirmed diagnosis of high risk non-muscle-invasive (T1, High Grade Ta and/or CIS) transitional cell carcinoma of the bladder.
- •2. In subjects who have papillary tumors (Ta and T1), a complete TURBT must have been performed, as per protocol.
- •3. Have been treated with adequate BCG therapy and have developed high risk NMBIC that is unresponsive to BCG therapy.
- •4. Have elected not to undergo, or are considered ineligible for radical cystectomy, as determined by the treating surgeon.
- •5. Have provided tissue for biomarker analysis from the most recent cystoscopy/TURBT procedures, from which tumor sample is available.
- •6. Have a performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG)
- •Performance Scale. (Max of 5% ECOG of 2.)
- •7. Demonstrate adequate organ function.
- •8. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication and be willing to use contraception in accordance with Section 5.7.2 of Protocol.
排除标准
- •1. Has muscle invasive (i.e. T2, T3, T4) locally advanced non-resectable or metastatic urothelial carcinoma.
- •2. Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium.
- •3. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •4. Has undergone any intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy/TURBT to starting trial treatment.
- •5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle 1, Day 1 or who has not recovered (i.e., <= Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •6. Has a known additional malignancy that is progressing or requires active treatment.
- •7. Has an active autoimmune disease that has required systemic treatment in past 2 years.
- •8. Has a diagnosis of immunidefiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the planned first dose of the study. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.
- •9. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- •10. Has an active infection requiring systemic therapy, including active or intractable urinary tract infection (UTI) in the last month.
- •11. Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
- •12. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137).
- •13. Has a known history of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies).
- •14. Has known active Hepatitis B or Hepatitis C.
- •15. Has received a live virus vaccine within 30 days of planned start of trial treatment.
- •16. Has had an allogenic tissue/solid organ transplant.
研究者
相似试验
进行中（未招募）
1 期
Pembrolizumab (MK-3475) and Pembrolizumab in combination with other agents in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapyon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004026-17-FIMerck Sharp & Dohme LLC320
进行中（未招募）
1 期
Pembrolizumab (MK3457) in high risk Non-muscle Invasive Bladder CancerEUCTR2014-004026-17-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc260
招募中
1 期
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCGon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: LLTClassification code: 10005004Term: Bladder cancer NOS Class: 10029104CTIS2022-502526-41-00Merck Sharp & Dohme LLC356
进行中（未招募）
1 期
Pembrolizumab (MK-3475) in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) TherapyEUCTR2014-004026-17-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.260
进行中（未招募）
1 期
Pembrolizumab (MK-3475), and pembrolizumab in combination with other investigational agents in high-risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapyon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004026-17-GRMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc320